<DOC>
	<DOCNO>NCT00001964</DOCNO>
	<brief_summary>This study test safety effectiveness combination three drug treat severe aplastic anemia prevent recurrence . Two drug use trial ATG cyclosporine standard combination therapy aplastic anemia . This study try improve therapy three way : 1 ) alter drug regimen allow drug work well ; 2 ) reduce risk kidney damage ; 3 ) add third drug mycophenolate mofetil try prevent disease relapse . Patients severe aplastic anemia suitable bone marrow donor decline bone marrow transplantation may participate study . Patients skin test ATG allergy , chest X-ray , blood test , bone marrow aspiration treatment begin . ATG start , infuse vein continuously 4 day . Ten day ATG stop , cyclosporine treatment begin , take twice day mouth either liquid capsule form continue 6 month . Also , first 2 week treatment , patient give full dose corticosteroid ( prednisone ) prevent serum sickness could develop side effect ATG therapy . The dosage decrease . Mycophenolate start time ATG , two daily dos mouth , continue 18 month . Patients hospitalize begin study . During time , blood drawn 3-week interval bone marrow examination repeat 3 month treatment begin . Additional test , include X-rays may require . After hospital discharge , patient follow outpatient basis 3-month interval . The patient physician perform blood test weekly kidney liver function test every 2 week cyclosporine therapy . Transfusions may require initially .</brief_summary>
	<brief_title>Combination Therapy Severe Aplastic Anemia</brief_title>
	<detailed_description>Severe acquire aplastic anemia ( SAA ) poor prognosis untreated . Bone marrow transplantation available minority patient due lack match sibling donor , advanced age patient , cost . Clinical study NIH elsewhere demonstrate excellent response rate improve survival immunosuppressive treatment . Laboratory data implicate underlying cytotoxic T-lymphocyte-mediated suppression hematopoiesis likely proximal cause disease patient . In earlier clinical protocol treat SAA cyclosporine A ( CSA ) ( 86-H-0007 ) , antithymocyte globulin ( ATG ) ( 87-H-0124 ) , combine ATG CSA ( 90-H-0146 ) . While intensive immunosuppression effective , relapse common patient also develop second hematologic complication like myelodysplasia . In protocol , modify regimen delay introduction cyclosporine promote ATG tolerizing effect add mycophenolate mofetil ( MMF ) , new agent , like ATG may relatively specific activate lymphocyte , effort reduce high relapse rate .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>INCLUSION CRITERIA : Only patient SAA admit , define : Bone marrow cellularity le 30 % . At least two follow blood count finding : absolute granulocyte count le 500/mm ( 3 ) ; platelet count less 20,000/mm ( 3 ) ; reticulocyte count le 60,000/mm ( 3 ) . Age great equal 1 year . Weight great 12 kg . EXCLUSION CRITERIA : Serum creatinine great 2 mg/dl estimate creatinine clearance le 40 ml/min . Underlying carcinoma , recent history radiation chemotherapy . Current pregnancy unwillingness treat oral contraceptive . Inability comprehend investigational nature study . Moribund status concurrent hepatic , renal , cardiac , neurologic , metabolic disease severity death within 7 10 day likely . Evidence etiology AA bone marrow failure , include positive clastogenic stress cytogenetic assay Fanconi anemia marrow chromosome abnormality typical myelodysplasia .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>May 6, 2016</verification_date>
	<keyword>Hematopoiesis</keyword>
	<keyword>Bone Marrow Failure</keyword>
	<keyword>Aplastic Anemia</keyword>
</DOC>